The company has been granted a patent from the European Patent Office, covering the treatment of fungal infections with compound glucono-δ-lactone (GDL).
The patent is valid in 36 European countries and can be kept in force until the 6th of April 2037. Gedea Biotech has previously announced that the corresponding patent is approved in the USA. Both patents comprise the use of the ingredient GDL in pHyph. GDL is a well-documented substance with a low risk of developing resistance, the company states.
“The currently approved European patent is part of our IP strategy. Hence, we have established exclusivity for our products in all important markets. In previous studies, Gedea has documented clinically relevant results with pHyph for the treatment of bacterial vaginosis and a follow-up, placebo-controlled study with the aim to confirm these results are currently being conducted at several European clinics. A study on vaginal fungal infection has been carried out with promising results and will be followed up with a larger study starting in Q1, 2022,” says Annette Säfholm, CEO, Gedea Biotech.
Expected to be granted in Japan shortly
Gedea Biotech has previously been granted patents in the United States, Eurasia (including Russia) and Israel for the treatment of vaginal fungal infections with GDL (pHyph). The corresponding patent is also expected to be granted in Japan shortly.